Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression signatures in anti-FGFR2IIIc monoclonal antibody-treated human colorectal cancer cells

ABSTRACT: To investigate the underlying mechanisms of the inhibitory effects of human anti-human FGFR2IIIc antibody on growth and migration of colorectal cancer cells, we used DNA microarray analysis to examine the cell signaling pathway alterations following the administration of anti-FGFR2IIIc antibody.

ORGANISM(S): Homo sapiens

PROVIDER: GSE38544 | GEO | 2012/06/08

SECONDARY ACCESSION(S): PRJNA168215

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression signatures in anti-FGFR2IIIc monoclonal antibody-treated human colorectal cancer cells

Project description:To investigate the underlying mechanisms of the inhibitory effects of human anti-human FGFR2IIIc antibody on growth and migration of colorectal cancer cells, we used DNA microarray analysis to examine the cell signaling pathway alterations following the administration of anti-FGFR2IIIc antibody. Cells were plated at a density of 2.5 M-CM-^W 105 cells in a 60-mm dish, and grown overnight. Then 100 M-NM-<g/mL of monoclonal anti-human FGFR2IIIc antibody was added in each dish. For control groups, an equal amount of anti-GFP antibody was added in another dish. After 48 hr, total RNA was isolated from cells. For use in DNA microarray analysis, 50 ng RNA from each group of cells was labeled using the Low Input Quick Amp Labeling kit. Labeled RNA was further purified using the Qiagen RNeasy Mini kit. Labeled cRNA was hybridized to the Agilent human 44k oligonucleotide microarray, and washed using Agilent Gene Expression washing buffer.

2012-06-07 | E-GEOD-38544 | biostudies-arrayexpress

Anti-tumor necrosis factor-alpha monoclonal antibody suppresses colorectal cancer growth in an orthotopic transplant mouse model

Project description:In order to investigate the effect of anti-TNFα mAb on colorectal cancer, we generated a orthotopic transplantation model of colorecatal cancer. We performed a comprehensive gene expression profiling analysis by extracting total RNA from cecal tumor of mice treated with and without anti-TNFα mAb (MP6-XT22)

2023-03-06 | GSE226619 | GEO

Genetic Study of anti-EGFR Antibody Therapy Response in Colorectal Carcinoma

Project description:Genetic Study of anti-EGFR Antibody Therapy Response in Colorectal Carcinoma

| PRJNA498496 | ENA

Nasal administration of anti-CD3 monoclonal antibody (Foralumab) modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects

Project description:Nasal administration of anti-CD3 monoclonal antibody (Foralumab) modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects

2022-11-05 | GSE217357 | GEO

Anti-tumor necrosis factor-alpha monoclonal antibody suppresses colorectal cancer growth in an orthotopic transplant mouse model

Project description:Anti-tumor necrosis factor-alpha monoclonal antibody suppresses colorectal cancer growth in an orthotopic transplant mouse model

| PRJNA940827 | ENA

Gephyrin interactome from mouse brain lysates using anti-gephyrin antibody and anti-gephyrin DARPins

Project description:In order to understand the protein interactors of the inhibitory synaptic scaffolding protein gephyrin, we precipitated gephyrin protein complexes from adult mouse brain lysates of both sexes using both a commercial anti-gephyrin antibody (clone 3B11), as well as anti-gephyrin Designed Ankyrin Repeat Domain (DARPin) protein binders.

2022-11-01 | PXD033641 | Pride

Gene expression alterations in human colon cancer xenograft treated with anti-VEGF antibody

Project description:Recent randomized clinical trial revealed the additional effect of bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF)-A, to conventional chemotherapy on survival of patients with metastatic colorectal cancer. However, a number of preclinical reports indicate resistant mechanisms to anti-angiogenic therapy in several tumor models. We investigated the phenotypic alterations of colorectal cancer xenograft during antiangiogenic therapy. TK-4, a solid tumor strain derived from human colon cancer, was orthotopically implanted into cecal walls of nude mice and treated with anti-VEGF antibody or control IgG for 35 days. Gene expression was analyzed using microarrays (Human Gene 1.0ST Array, Affymetrix).

2013-05-25 | E-GEOD-47087 | biostudies-arrayexpress

Evaluation of anti-tumorigenic effects of anti-Lipocalin2 (anti-LCN2) monoclonal antibody against human cervical cancer xenografts in athymic nude mice

Project description:This study investigated the impact of an anti-LCN2 monoclonal antibody on STR-authenticated HeLa cells using a xenograft model in athymic nude mice. Treatment of tumors with anti-LCN2 antibody resulted in 39 – 60% reduction in tumor volume. RNA extracted from the tumors post-treatment was sequenced and aligned to human and mouse genome separately. Differential expression analysis of human mapped overexpressed genes in treated tumor revealed suppression of pro-tumorigenic TNF- and IL17 signalling pathways, whereas the corresponding mouse-mapped genes indicated pathways including activation of T-cells and T-cell mediated killing in treated tumors. M2 mouse macrophage markers showed a decline under treatment signifying tumor regression. This observed T-cell activation and debilitation of M2 mouse macrophages by anti-LCN2 underlies its potential as an immune sensitizer that can potentially devour tumor cells through T-cell mediated cytotoxicity.

2023-12-31 | GSE242667 | GEO

Luminal metabolome profiles of human microbiota-associated (HMA) mice treated with anti-IL-22 antibody or control antibody

Project description:Luminal (fecal) metabolome of anti-IL-22 antibody-treated HMA mice and control antibody-treated HMA mice were compared.

2019-12-22 | ST001301 | MetabolomicsWorkbench

The Sesquiterpene Lactone-Rich Fraction of Inula helenium L. Enhances the Antitumor Effect of Anti-PD-1 Antibody in Colorectal Cancer: Integrative Phytochemical, Transcriptomic, and Experimental Analyses

Project description:Treatment strategies combining immune checkpoint inhibitors with sesquiterpene lactones have attracted much attention as a promising approach for cancer treatment. We systemically analyzed gene expression profiles of cells in response to two major sesquiterpene lactones, alantolactone and isoalantolactone, and determined whether the sesquiterpene lactone-rich fraction of Inula helenium L. (SFIH) enhances the antitumor effect of anti-PD-1 antibody in MC38 colorectal can-cer-bearing mice. Gene expression and pathway analysis using RNA sequencing data were used to identify the SFIH-driven combined activity with anti-PD-1 antibody. The results showed that SFIH significantly enhanced the antitumor effect of anti-PD-1 antibody by reducing tumor growth and increasing the survival time of mice. Specifically, SFIH exhibited antitumor activity when com-bined with anti-PD-1 antibody, and the effects were further enhanced compared with monotherapy. An analysis of immune cells indicated that combination treatment with SFIH and anti-PD-1 an-tibody significantly increased the proportion of CD8+ T cells. Moreover, combination treatment enhanced antitumor immunity by decreasing the population of myeloid-derived suppressor cells and increasing the number of M1-like macrophages. Pathway enrichment analysis revealed that combination therapy activated immune-related pathways to a greater extent than monotherapy. In conclusion, our integrative analysis demonstrates that SFIH enhances the response of murine tumors to anti-PD-1 antibody. These findings provide insight into developing integrative ther-apeutics and molecular data for the use of natural products as an adjunct treatment for colorectal cancer.

2022-12-30 | GSE221784 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data